PAX8 is a transcription factor that acts as a master switch during the formation of the thyroid gland, kidneys, and female reproductive tract, then gets co-opted by several cancers to fuel their growth and survival. It belongs to the paired-box family of genes, a set of developmental regulators conserved across hundreds of millions of years of evolution. What makes PAX8 especially interesting is the way its normal developmental role becomes a liability in cancer: the same gene that tells embryonic tissues how to grow and specialize can, when reactivated or amplified in adult cells, help tumors resist treatment and spread.
How PAX8 Builds the Thyroid Gland
During embryonic development, PAX8 is one of the earliest genes to switch on in the tissue that will become the thyroid. It appears in the median thyroid anlage and the fourth pharyngeal arch before the other two major thyroid transcription factors, TTF-1 and TTF-2, begin their work.1Modern Pathology. Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms The interplay between these three factors drives the gland’s formation, its migration to its final position in the neck, and its maturation into a functional hormone-producing organ.
PAX8 does not just help build the thyroid and then go quiet. It remains active in adult thyroid cells, where it keeps the genes for thyroid-specific proteins turned on. Reintroducing PAX8 into thyroid cells that have lost their differentiated state is enough to reactivate the genes encoding thyroglobulin, thyroperoxidase, and the sodium/iodide symporter, the molecular machinery the thyroid needs to produce hormones.2PubMed Central. Pax8 has a key role in thyroid cell differentiation In other words, PAX8 is not merely an embryonic scaffold that gets discarded after construction; it is more like a foreman who stays on site indefinitely to keep operations running.
Genome-wide studies have mapped PAX8’s reach across thyroid cell DNA and found it regulates a broad network of genes involved in cell growth, differentiation, programmed cell death, cell polarity, and adhesion. PAX8 works alongside chromatin-remodeling partners like CTCF and Sp1, both of which help shape how tightly DNA is packaged and therefore which genes are accessible. These partners also help PAX8 activate the sodium/iodide symporter gene, a key step in iodine uptake.3PubMed Central. Genome-wide analysis of Pax8 binding provides new insights into thyroid functions Gene silencing experiments in rat thyroid cells have confirmed a long list of direct downstream targets, including genes in the Wnt signaling pathway, ion channels, and growth factor regulators.4PLOS ONE. Identification of Novel Pax8 Targets in FRTL-5 Thyroid Cells by Gene Silencing and Expression Microarray Analysis
Beyond the Thyroid: Kidneys and the Reproductive Tract
PAX8’s developmental resume extends well past the thyroid. In the kidney, it is one of the master transcriptional regulators that define the kidney field, the patch of embryonic tissue from which the kidney will form. In frog embryos, retinoic acid signaling acts upstream of PAX8 and another gene called lhx1 to specify which cells will become renal precursors.5PubMed. Retinoic acid control of pax8 during renal specification of Xenopus pronephros involves hox and meis3 In the adult human kidney, PAX8 protein is detectable in epithelial cells lining every segment of the renal tubules, from the proximal tubules through to the renal papillae, as well as in the parietal cells of Bowman’s capsule.6Modern Pathology. Expression of PAX8 in normal and neoplastic renal tissues: an immunohistochemical study
PAX8 also plays a role in building the female reproductive tract. It has been detected in the embryonic Müllerian ducts, the structures that give rise to the fallopian tubes, uterus, and upper vagina.7PubMed. Pax8: a marker for carcinoma of Müllerian origin in serous effusions In adult women, PAX8 marks the secretory cells of the fallopian tube epithelium, a detail that becomes central to understanding how the most common and lethal form of ovarian cancer arises.
What Happens When PAX8 Is Missing from Birth
Germline mutations in PAX8 can cause congenital hypothyroidism through thyroid dysgenesis, a condition in which the thyroid gland fails to develop properly. Researchers identified PAX8 mutations in both sporadic and familial cases of thyroid dysgenesis, with each mutation located in the paired domain of the protein and causing a severe reduction in its ability to bind DNA.8PubMed. PAX8 mutations associated with congenital hypothyroidism caused by thyroid dysgenesis These cases are rare, but they provided early proof that PAX8 is not merely associated with thyroid development; it is required for it. Without a functional copy, the gland may be absent, shrunken, or stuck in the wrong anatomical position.
The PAX8/PPARγ Fusion in Follicular Thyroid Cancer
One of the clearest links between PAX8 and cancer involves a specific chromosomal rearrangement found in follicular thyroid cancer. A translocation between chromosomes 2 and 3 fuses the PAX8 gene with PPARγ, a nuclear receptor normally involved in fat cell differentiation and metabolism. The resulting fusion protein, often abbreviated PPFP, is relatively common in follicular thyroid carcinomas and may represent an early, initiating event in the development of this cancer subtype.9PubMed Central. The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer
The fusion is thought to work in part by disrupting the normal tumor-suppressive functions of PPARγ while simultaneously redirecting the transcriptional activity of PAX8 toward pro-growth targets. Detecting this fusion in biopsy specimens helps pathologists distinguish follicular thyroid cancer from benign thyroid nodules, a distinction that is notoriously difficult on cytology alone.
PAX8 as a Lineage-Survival Oncogene in Ovarian Cancer
The relationship between PAX8 and ovarian cancer is one of the more striking stories in cancer biology. High-grade serous ovarian carcinoma, the deadliest subtype of gynecologic cancer, originates in most cases from the secretory cells lining the fimbriated end of the fallopian tube.10PubMed Central. PAX8 as a Potential Target for Ovarian Cancer: What We Know so Far These are the same cells that normally express PAX8 during development and adult life. When these cells become cancerous, they keep PAX8 switched on, and roughly 90% of high-grade serous ovarian cancers stain positive for the protein.11PubMed Central. PAX8 modulates the tumor microenvironment of high grade serous ovarian cancer through changes in the secretome
PAX8 is not just a bystander that cancer cells happen to retain. Large-scale genetic screens across cancer cell lines found that PAX8 is focally amplified in about 16% of high-grade serous ovarian cancers and is overexpressed compared to other cancer types. Suppressing PAX8 selectively killed ovarian cancer cells while leaving other cell types relatively unharmed, a hallmark of what researchers call a lineage-specific dependency.12PubMed Central. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer In practical terms, the cancer cells are addicted to a gene they inherited from their tissue of origin. Take it away, and they die.
The downstream effects of PAX8 in these tumors are multifaceted. Knocking down PAX8 in ovarian cancer cell lines increases programmed cell death and reduces levels of FOXM1, a transcription factor linked to cell proliferation.13PubMed Central. Loss of PAX8 in high-grade serous ovarian cancer reduces cell survival despite unique modes of action in the fallopian tube and ovarian surface epithelium PAX8 also drives an autocrine signaling loop through FGF18 that promotes cell migration.14PubMed Central. PAX8 regulon in human ovarian cancer links lineage dependency with epigenetic vulnerability to HDAC inhibitors And in mouse xenograft experiments, silencing PAX8 in SKOV-3 ovarian cancer cells significantly inhibited proliferation, invasion, and tumor growth in living animals.15PubMed Central. A role for PAX8 in the tumorigenic phenotype of ovarian cancer cells
PAX8 and Drug Resistance in Ovarian Cancer
Beyond fueling tumor growth, PAX8 appears to help ovarian cancer cells resist treatment. A multi-omic study found a PAX8-driven gene signature associated with tumor stemness, a property tied to therapy resistance. When the expression of this six-gene signature was measured in serous ovarian cancer patients, those whose tumors had higher expression of the signature responded worse to platinum-based chemotherapy, and patients resistant to treatment showed significantly elevated levels of these genes.16NAR Genomics and Bioinformatics. Integrative multi-omic analysis reveals a PAX8-driven gene network linking tumor stemness to therapy response in ovarian cancer When researchers depleted PAX8 from ovarian cancer cell lines in the lab, the cells became significantly more sensitive to cisplatin, carboplatin, and paclitaxel, the standard drugs used to treat the disease.
The resistance connection extends to ferroptosis, a form of regulated cell death driven by iron-dependent damage to cell membranes. Genome-wide CRISPR screens identified PAX8 as a ferroptosis-resistance factor in ovarian cancer. Depleting PAX8 made cancer cells that depend on GPX4, a key ferroptosis-defense enzyme, significantly more sensitive to GPX4 inhibitors. PAX8 appears to protect these cells in part by supporting glutathione synthesis, the cellular antioxidant system that keeps ferroptosis in check.17PubMed. Targeting PAX8 sensitizes ovarian cancer cells to ferroptosis by inhibiting glutathione synthesis
Early-stage experiments have explored whether PAX8 can be pharmacologically targeted. Curcumol, a natural compound, has been shown to inhibit PAX8 and reduce the proliferation and invasiveness of ovarian cancer cells. When combined with niraparib, a PARP inhibitor already used clinically, the combination showed stronger anti-tumor activity than either agent alone.18PubMed Central. Curcumol Targeting PAX8 Inhibits Ovarian Cancer Cell Migration and Invasion and Increases Chemotherapy Sensitivity of Niraparib Separately, a high-throughput screen of nearly 70,000 compounds identified small molecules that inhibit PAX family transcription without blocking their DNA binding. Instead, these compounds prevent PAX proteins from recruiting a co-activator called PTIP and promoting a specific histone modification needed to activate target genes.19Cell Chemical Biology. Small-molecule inhibitors of Pax transcription activation These are preclinical findings, but they suggest that directly targeting PAX8’s transcriptional machinery is at least chemically feasible.
PAX8 in Kidney Tumors
Because PAX8 is expressed throughout normal kidney tubular epithelium, it is no surprise that renal tumors frequently retain the protein. One study found PAX8 staining in about 83% of renal tumors overall, with positivity in 80% of clear cell renal cell carcinomas, 95% of papillary tumors, and 100% of chromophobe tumors.20PubMed Central. PAX-8 expression in renal tumours and distant sites: a useful marker of primary and metastatic renal cell carcinoma? A separate study using a different set of samples reported similar numbers: about 98% of clear cell RCC, 90% of papillary RCC, 95% of oncocytomas, and 82% of chromophobe RCC.6Modern Pathology. Expression of PAX8 in normal and neoplastic renal tissues: an immunohistochemical study PAX8 is also detectable in about 85% of metastatic renal tumors, which matters when a pathologist encounters a tumor that has spread and needs to figure out where it came from.
How Pathologists Use PAX8 to Trace Unknown Tumors
When a cancer turns up at a metastatic site without an obvious primary tumor, pathologists rely on panels of protein markers to narrow down its origin. PAX8 has become one of the most useful markers in this detective work. A comprehensive analysis across hundreds of epithelial tumors showed that PAX8 is highly sensitive for thyroid, renal, Müllerian (ovarian, fallopian tube, endometrial), and thymic tumors. Just as valuably, it is negative in lung adenocarcinomas, breast cancers, adrenal tumors, and the vast majority of gastrointestinal cancers.21The American Journal of Surgical Pathology. A Comprehensive Analysis of PAX8 Expression in Human Epithelial Tumors Another study testing over 1,100 cases confirmed this specificity, finding PAX8 negative in cancers of the colon, breast, prostate, liver, stomach, esophagus, and in melanomas.22Applied Immunohistochemistry & Molecular Morphology. Expression of PAX8 in Normal and Neoplastic Tissues
PAX8 is now included in standard immunohistochemical panels used to work up carcinomas of unknown primary, alongside lineage-restricted transcription factors like CDX2, TTF-1, and NKX3-1.23Advances in Anatomic Pathology. Metastatic Carcinoma of Unknown Primary: Diagnostic Approach Using Immunohistochemistry If a metastatic adenocarcinoma stains positive for PAX8 but negative for TTF-1, the top considerations shift toward renal or gynecologic origin. If both PAX8 and TTF-1 are positive, thyroid becomes the leading candidate. The staining pattern does not give a definitive diagnosis by itself, but it narrows the differential considerably and directs further testing.
The Antibody Cross-Reactivity Problem
There is an important technical wrinkle that has caused confusion in the literature. Not all PAX8 antibodies are equal. Polyclonal antibodies directed against the N-terminal region of PAX8 share enough sequence similarity with PAX5, a related transcription factor expressed in B cells, that they can produce false-positive staining in lymphomas and other B-cell neoplasms. Studies confirmed that reactive and neoplastic B cells stain positive with the N-terminal polyclonal antibody but are completely negative with antibodies targeting the C-terminal region, and PAX8 mRNA is undetectable in B-cell lymphoma cell lines.24PubMed. N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas In short, B cells do not actually express PAX8; earlier reports claiming they did were artifacts of antibody cross-reactivity.
The same problem has affected reports of PAX8 staining in lung and thymic tumors. When a monoclonal PAX8 antibody was compared head-to-head with the polyclonal version, many tumors that appeared positive with the polyclonal reagent turned out to be expressing PAX5 or PAX6 instead. RNA-level testing confirmed that no PAX8 mRNA was present in these tumors outside of thyroid cases.25PubMed. Utility of PAX8 mouse monoclonal antibody in the diagnosis of thyroid, thymic, pleural and lung tumours: a comparison with polyclonal PAX8 antibody A similar story played out in pancreatic neuroendocrine tumors. Initial reports using polyclonal antibodies suggested PAX8 was expressed in islet cells and pancreatic neuroendocrine tumors. A re-evaluation using a monoclonal antibody found no staining at all, and further analysis showed the polyclonal antibody had been recognizing PAX6 protein in the islets.26PubMed Central. Immunohistochemical assessment of Pax8 expression during pancreatic islet development and in human neuroendocrine tumors
For pathologists, the practical takeaway is that monoclonal PAX8 antibodies provide more reliable results. Older studies using polyclonal reagents should be interpreted with caution, and unusual staining patterns in tissues where PAX8 expression has not been confirmed at the RNA level deserve skepticism. This matters clinically: a false-positive PAX8 result in a lung tumor could misdirect the diagnostic workup toward a renal or gynecologic primary.
MicroRNA Regulation of PAX8 in Cancer
PAX8 levels in cancer cells are not determined solely by DNA amplification or transcription factor activity. Small RNA molecules called microRNAs also modulate how much PAX8 protein gets produced. In thyroid carcinogenesis, a regulatory circuit involving miR-146b-3p, PAX8, and the sodium/iodide symporter (NIS) appears to influence how differentiated thyroid cancer cells remain. According to prediction tools and expression data, at least five upregulated microRNAs, including miR-146b-3p, miR-182, miR-221, miR-222, and let-7e, are predicted to target PAX8. At the same time, some downregulated microRNAs also target PAX8, potentially counterbalancing the inhibitory effects.27Cancer Research. The miR-146b-3p/PAX8/NIS Regulatory Circuit Modulates the Differentiation Phenotype and Function of Thyroid Cells during Carcinogenesis This tug-of-war between opposing microRNAs helps explain why PAX8 levels vary from tumor to tumor and why some thyroid cancers lose the ability to take up iodine, a property that matters for radioactive iodine treatment.
Evolutionary Roots of the PAX2/5/8 Family
PAX8 did not appear out of nowhere. It belongs to the PAX2/5/8 subfamily, a group of closely related transcription factors that share a common ancestor predating the emergence of vertebrates. In sea squirt relatives called larvaceans, a single ancestral PAX2/5/8 gene is expressed in the endostyle (a thyroid precursor), sensory tissues, and sites of tissue remodeling, hinting that the developmental roles of PAX8 in the thyroid, kidney, and sensory organs trace back to the common ancestor of all chordates.28PubMed Central. Evolution of developmental roles of Pax2/5/8 paralogs after independent duplication in urochordate and vertebrate lineages
Comparative analysis suggests that PAX2 and PAX5 are more closely related to each other than either is to PAX8. The evolutionary distance between PAX8 and the ancestral gene is significantly greater than for PAX2 or PAX5, supporting the idea that PAX8 arose through a local gene duplication event rather than the large-scale genome duplications that produced the other two family members.29PubMed Central. Evolutionary History of Chordate PAX Genes: Dynamics of Change in a Complex Gene Family Despite being the newest member of the trio, PAX8’s DNA-binding domain is highly conserved. Its paired box domain consists of two helix-turn-helix motifs separated by a flexible linker, a structural arrangement shared with family members PAX5 and PAX6 and regulated by a redox mechanism involving two specific cysteine residues.30PubMed Central. The solution structure of DNA-free Pax-8 paired box domain accounts for redox regulation of transcriptional activity in the pax protein family That the same structural features appear across such distantly related PAX proteins speaks to how tightly evolution has conserved this DNA-binding architecture over hundreds of millions of years.